In a multicenter, open‐label phase I/II clinical trial, investigators evaluated the safety and effectiveness of FLT180a in patients with severe or moderately severe hemophilia B, featured by factor IX levels ≤2% of the normal value. Here, F9 is linked to hemophilia B.